← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT05301608

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Trial Parameters

Condition Healthy
Sponsor Johns Hopkins University
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2022-03-03
Completion 2026-07-01
Interventions
PsilocybinPlacebo

Brief Summary

This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity.

Eligibility Criteria

Inclusion Criteria: * 18 to 75 years old * Have given written informed consent * Have at least a high-school level of education or equivalent (e.g. GED) and be fluent in English * Be healthy and psychologically stable as determined by screening for medical and psychiatric problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests * Agree to consume approximately the same amount of caffeine-containing beverage (e.g. coffee, tea) that he/she consumes on a usual morning, before arriving at the research unit on the morning of the drug session day. If the participant does not routinely consume caffeinated beverages, he/she must agree not to do so on the session day. * Agree to refrain from using any psychoactive drugs, including alcoholic beverages and nicotine, within 24 hours of each drug administration. The exception is caffeine. * Agree not to take any "as-needed" medications o

Related Trials